Metastatic Pancreatic Ductal Adenocarcinoma research hub
8 indexed studies · 5 currently recruiting
- recruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
United States · Australia · Israel - recruitingPHASE2, PHASE3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
This study looks at a new medicine called ponsegromab for advanced pancreatic cancer that has spread, especially when patients have lost a lot of weight and feel very tired. It aims to see if adding ponsegromab to standard chemotherapy helps more than chemotherapy alone.
United States · Australia · Belgium - authorisedTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
This clinical trial is testing a new targeted medicine called atebimetinib for advanced pancreatic cancer. Doctors want to see if adding this drug to standard chemotherapy helps people live longer and improves their quality of life compared to standard chemotherapy alone.
Spain · Czechia · Hungary - recruitingPhase I and Phase II (Integrated)- Other
An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma
This clinical trial is testing an experimental medicine called mitazalimab combined with standard chemotherapy. It aims to find out if this combination is safe and effective at shrinking tumours in adults with advanced pancreatic cancer that has spread to other parts of the body.
France · Belgium · Spain - authorisedPhase II and Phase III (Integrated)
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
This clinical trial is testing a new targeted medicine called telisotuzumab adizutecan, combined with chemotherapy, for people with advanced pancreatic cancer. Doctors want to see if this new combination shrinks tumours better and helps people live longer compared with standard chemotherapy treatments currently used on the NHS.
Portugal · Spain · France - recruitingPhase II and Phase III (Integrated)
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
This study is testing a new drug, SBP-101, alongside standard treatments (Nab-paclitaxel and Gemcitabine) for advanced pancreatic cancer that hasn't been treated before. Researchers want to see if adding SBP-101 helps people live longer.
Italy · Belgium · Germany - active not recruitingPHASE3
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This study is testing a new drug, quemliclustat, alongside standard chemotherapy for pancreatic cancer that has spread. Researchers want to see if adding quemliclustat helps people live longer compared to chemotherapy alone. It's a phase 3 trial, meaning it's in the final stages of testing.
United States · Australia · Austria - recruitingPhase II
A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma
This trial tests a new drug called ginisortamab for advanced pancreatic cancer that has spread. Researchers want to find out the safest dose, check for side effects, and see if combining ginisortamab with standard chemotherapy or targeted medicines helps slow or shrink tumour growth.
United Kingdom · England · Northern Ireland